ClinicalTrials.gg
CompletedNCT04508907Updated Oct 29, 2026Results posted

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

A Phase 4 interventional study of Mavyret in Hepatitis C, Kidney Transplant; Complications and Heart Transplant Infection, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
227
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing glecaprevir and pibrentasvir in Hepatitis C — 3 open to participants now, 3 under way, 1 of them phase 3. glecaprevir and pibrentasvir · Hepatitis C.

Enrollment
10th of 43
227 · median 100
Started
2020
with 3 others
Phase 4
10 of 43
1 open now
Registered
34th of 43
by date
Lead sponsor
1 of 43
Mayo Clinic

Among the 43 studies testing glecaprevir and pibrentasvir in Hepatitis C, this one is the 10th largest by enrollment, is one of 4 that started in 2020, is one of 10 in phase 4, and was the 34th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

3 of the 43 studies testing glecaprevir and pibrentasvir in Hepatitis C are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About glecaprevir and pibrentasvir

glecaprevir and pibrentasvir: first FDA approval 2017 (MAVYRET), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing glecaprevir and pibrentasvir in Hepatitis C, or all of them as a file.
02

Study summary

This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.

03

Conditions studied

  • Hepatitis C
  • Kidney Transplant; Complications
  • Heart Transplant Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Listed kidney, heart, lung and/or pancreas patients who are negative for chronic infection
  • Willing to accept and consent for accepting hepatitis C positive graft

Exclusion criteria

Exclusion criteria:

  • Existing chronic liver disease (liver cirrhosis)
  • Concomitant infection with or Chronic
  • Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired infection
  • Pregnancy (Pregnant patients do not undergo solid organ transplants)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    Arm 1: Pre-emptive Treatment Arm

    Single arm study were all recipients of HCV viremic organs will receive combination therapy.

    Drug: Mavyret

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of Prevention of HCV Viremia in Recipients of HCV Viremic Solid Organs

    The percentage of patients who did not become HCV viremic using this preemptive treatment protocol.

    Time frame: 3 months

  2. Graft and Patient Survival

    The number of subjects alive at 1-year and the number of subjects with a functioning transplanted organ (graft survival) at 1-year.

    Time frame: 1 year

07

Results

Posted Oct 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Pre-emptive Treatment Arm
Started227
Completed227
Not completed0

Outcome measures

PrimaryRate of Prevention of HCV Viremia in Recipients of HCV Viremic Solid Organs

The percentage of patients who did not become HCV viremic using this preemptive treatment protocol.

Time frame:
3 months
Reported as:
Number · percentage of patients
Rate of Prevention of HCV Viremia in Recipients of HCV Viremic Solid Organs
percentage of patientsArm 1: Pre-emptive Treatment Arm
Rate of Prevention of HCV Viremia in Recipients of HCV Viremic Solid Organs99.6
PrimaryGraft and Patient Survival

The number of subjects alive at 1-year and the number of subjects with a functioning transplanted organ (graft survival) at 1-year.

Time frame:
1 year
Reported as:
Count of participants · Participants
Graft and Patient Survival
ParticipantsArm 1: Pre-emptive Treatment Arm
Graft Survival222
Patient Survival219

Adverse events

Collected over Adverse events were collected from the start of study drug administration through 30 days after the last dose of study drug (approximately 37 days total). Deaths were assessed up to 1 year.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Pre-emptive Treatment Arm8/227 (3.5%)0/227 (0%)0/227 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1: Pre-emptive Treatment Arm
Mean60 (52 to 68)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Pre-emptive Treatment Arm
Female75
Male152
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: Pre-emptive Treatment Arm
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported227
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Pre-emptive Treatment Arm
American Indian or Alaska Native8
Asian24
Native Hawaiian or Other Pacific Islander1
Black or African American39
White116
More than one race0
Unknown or Not Reported39
Region of Enrollment
Region of Enrollment(participants)Arm 1: Pre-emptive Treatment Arm
United States227
08

Study locations

1 site
  • Mayo Clinic in Arizona
    Phoenix, Arizona 85054, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Nov 2025, 61 months.

Results were first posted in Oct 2026, 11 months after primary completion.

Of 56 non-industry phase 4 interventional studies under Hepatitis C, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 61 months is above that.

Counting every sponsor, half of 58 studies reached it within 24 months; a quarter within 16 and three quarters within 48.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Nov 2025, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2020
First posted
Aug 11, 2020
StartActual
Sep 10, 2020
Primary completionActual
Nov 1, 2025
CompletionActual
Nov 1, 2025was Nov 2026
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Results
Results posted
posted Oct 29, 2026
Study completion
Nov 1, 2026→Nov 1, 2025 (actual)
Oct 29, 2026
Enrollment
200 (estimated)→227 (actual)
Oct 29, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedRate of preventionPrevention of HCV viremiaViremia in recipientsRecipients of HCV viremic solid organsViremic Solid OrgansTime frame: 3 months
  • EditedGraft and patient survivalPatient SurvivalTime frame: 1 year
Oct 29, 2026
Documents
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    Results posted
    Documents Study protocol ↗ posted
    Study completion Nov 1, 2026→Nov 1, 2025 (now actual)
    Enrollment 200 (estimated)→227 (actual)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedRate of preventionPrevention of HCV viremiaViremia in recipientsRecipients of HCV viremic solid organsViremic Solid OrgansTime frame: 3 months
    • EditedGraft and patient survivalPatient SurvivalTime frame: 1 year
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04508907
Lead sponsor
Mayo Clinic
Responsible party
Bashar Aqel (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 11, 2020
Start date
Sep 10, 2020
Primary completion
Nov 1, 2025
Completion
Nov 1, 2025
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Bashar A Aqel
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glecaprevir and pibrentasvir

Start the discussion